Centenial Surgic

Why is Centenial Surgical Suture Ltd falling/rising?

As of 28-Jun, Centenial Surgical Suture Ltd's stock price is Rs 73.20, unchanged from the previous close, and has declined -6.53% over the last two days. The stock is underperforming its sector and has decreased significantly year-to-date and over the past year, indicating a bearish trend exacerbated by reduced investor participation.

As of 28-Jun, Centenial Surgical Suture Ltd's stock price is currently at Rs 73.20, showing no change from the previous close. The stock has been experiencing a downward trend, having fallen consecutively for the last two days, resulting in a total decline of -6.53% during this period. Additionally, the stock is trading close to its 52-week low, just 0.22% away from Rs 73.04.<BR><BR>In terms of performance, the stock has underperformed its sector by -2.37% today and has seen a significant decline of -21.84% over the past month, compared to a modest increase of +0.80% in the Sensex. Year-to-date, the stock has decreased by -28.79%, while the Sensex has only fallen by -9.53%. Over the past year, the stock has plummeted by -50.79%, contrasting sharply with the Sensex's decline of -6.83%. <BR><BR>Moreover, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Investor participation has also decreased significantly, with delivery volume dropping by -69.48% against the 5-day average. This lack of investor interest further contributes to the stock's downward trajectory. <BR><BR>Overall, the combination of consecutive price declines, underperformance relative to the sector, and reduced investor participation are key factors contributing to the falling stock price of Centenial Surgical Suture Ltd.

Which are the latest news on Centenial Surgic?

How big is Centenial Surgic?

As of 10th June, Centenial Surgical Suture Ltd has a market capitalization of 30.00 Cr and reported net sales of 53.84 Cr with a net loss of 2.21 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Centenial Surgical Suture Ltd has a market capitalization of 30.00 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 53.84 Cr. The sum of Net Profit for the latest 4 quarters shows a loss of 2.21 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 30.75 Cr, and Total Assets amount to 84.55 Cr.

Who are in the management team of Centenial Surgic?

The management team of Centenial Surgic includes Vijay Majrekar (Chairman/Executive Director), Anuradha Kashikar (Executive Director/Whole Time Director), Devraj T Poojary (Executive Director/Whole Time Director), and four Independent Non-Executive Directors: B S Limaye, Sunil C Modi, Jagadish B Shetty, and N M Vora.

The management team of Centenial Surgic includes the following individuals:<BR><BR>1. **Vijay Majrekar** - Chairman / Executive Director<BR>2. **Anuradha Kashikar** - Executive Director / Whole Time Director<BR>3. **Devraj T Poojary** - Executive Director & Whole Time Director<BR>4. **B S Limaye** - Independent Non-Executive Director<BR>5. **Sunil C Modi** - Independent Non-Executive Director<BR>6. **Jagadish B Shetty** - Independent Non-Executive Director<BR>7. **N M Vora** - Independent Non-Executive Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Centenial Surgic?

Centenial Surgic's peers include KMS Medisurgi, N G Industries, and Sunrest Lifescie, among others. Management risk varies, with excellent ratings for N G Industries and Sunrest Lifescie, while Centenial Surgic has below-average risk and a 1-year return of -39.57%.

Peers: The peers of Centenial Surgic are KMS Medisurgi, N G Industries, Samsrita Labs, Deccan Healthcar, GKB Ophthalmics, Chennai Meena, Tejnaksh Health., Transgene Biotek, Sunrest Lifescie, and Galaxy Medicare.<BR><BR>Quality Snapshot: Excellent management risk is observed at N G Industries and Sunrest Lifescie, while Average management risk is found at KMS Medisurgi and the rest. Below Average management risk is noted at Deccan Healthcar, GKB Ophthalmics, Centenial Surgic, Tejnaksh Health., and the rest. Growth is rated as Excellent at Sunrest Lifescie, Good at Deccan Healthcar and GKB Ophthalmics, Below Average at KMS Medisurgi, N G Industries, and Centenial Surgic, and the rest do not qualify. Capital Structure is rated as Good at KMS Medisurgi, N G Industries, Deccan Healthcar, GKB Ophthalmics, and Tejnaksh Health., Average at Centenial Surgic, and the rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is KMS Medisurgi at 6.24%, while the peer with the lowest is N G Industries at -26.21%. Centenial Surgic's 1-year return is -39.57%, which is lower than both of these peers. Additionally, the peers with negative six-month returns include Deccan Healthcar, GKB Ophthalmics, Tejnaksh Health., and N G Industries.

What does Centenial Surgic do?

Centenial Surgical Suture Ltd manufactures and sells surgical sutures in the healthcare industry. As of March 2026, it reported net sales of 13 Cr and a net loss of 2 Cr, with a market cap of INR 30 Cr.

Overview: <BR>Centenial Surgical Suture Ltd is engaged in the manufacture and sale of surgical sutures within the healthcare services industry and operates as a micro-cap company.<BR><BR>History: <BR>Incorporated in 1995, Centenial Surgical Suture has remained focused on its core business of surgical sutures. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 13 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -2 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 30 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.37 <BR>Return on Equity: -7.74% <BR>Price to Book: 1.04<BR><BR>Contact Details: <BR>Address: Plot No F-29, MIDC Industrial Area Murbad Thane Maharashtra : 421401 <BR>Tel: 91-2524-222905/222906 <BR>Email: admin@centenialindia.com <BR>Website: http://www.centenialindia.com

Should I buy, sell or hold Centenial Surgical Suture Ltd?

Are Centenial Surgical Suture Ltd latest results good or bad?

Centenial Surgical Suture Ltd's latest results are negative, showing a net loss of ₹2.31 crores in Q4 FY26, a 95.8% decline year-over-year, with revenue dropping 15.34% from the previous quarter. The company's stock has also underperformed, falling 37.76% over the past year.

Centenial Surgical Suture Ltd's latest results indicate a troubling performance. In the fourth quarter of FY26, the company reported a net loss of ₹2.31 crores, which is a significant decline of 95.8% year-over-year. Revenue also fell to ₹12.58 crores, down 15.34% from the previous quarter and 5.48% compared to the same quarter last year. This marks the lowest quarterly revenue for the fiscal year.<BR><BR>The operating margin has dropped to 7.39%, down from 15.55% in the same quarter last year, reflecting severe operational challenges. Additionally, interest costs surged by 531% quarter-over-quarter, further exacerbating the financial strain.<BR><BR>Overall, the company's stock has underperformed significantly, declining 37.76% over the past year, contrasting sharply with the broader Healthcare Services sector, which has seen an 18.74% increase. These results suggest that Centenial Surgical Suture is facing substantial operational and financial difficulties, making the latest results decidedly negative.

When is the next results date for Centenial Surgical Suture Ltd?

The next results date for Centenial Surgical Suture Ltd is February 12, 2026.

The next results date for Centenial Surgical Suture Ltd is scheduled for February 12, 2026.

How has been the historical performance of Centenial Surgic?

Centenial Surgic's historical performance shows fluctuating net sales, increasing from 51.19 Cr in Mar'24 to 53.52 Cr in Mar'25, but it reported a loss with a profit after tax of -1.46 Cr in Mar'25, despite improved operating efficiency and cash flow from operations. Total liabilities and assets rose to 84.55 Cr in Mar'25, indicating financial challenges.

Answer:<BR>The historical performance of Centenial Surgic shows a fluctuating trend in net sales and profitability over the years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>Centenial Surgic's net sales increased from 51.19 Cr in Mar'24 to 53.52 Cr in Mar'25, following a dip in Mar'23. The total operating income also rose to 53.52 Cr in Mar'25 from 51.19 Cr in Mar'24. However, the company's total expenditure, excluding depreciation, increased slightly to 47.26 Cr in Mar'25 from 46.18 Cr in Mar'24. Operating profit, excluding other income, improved to 6.26 Cr in Mar'25 from 5.01 Cr in Mar'24, indicating better operational efficiency. Despite this, the company reported a profit before tax of -1.62 Cr in Mar'25, a decline from a profit of 1.27 Cr in Mar'24, leading to a profit after tax of -1.46 Cr in Mar'25 compared to 1.13 Cr in Mar'24. The total liabilities rose to 84.55 Cr in Mar'25 from 79.15 Cr in Mar'24, while total assets also increased to 84.55 Cr in Mar'25 from 79.15 Cr in Mar'24. The cash flow from operating activities improved to 17.00 Cr in Mar'25 from 6.00 Cr in Mar'24, but cash flow from investing activities was negative at -11.00 Cr. Overall, the company faced challenges in profitability despite an increase in sales and operating income.

Is Centenial Surgic overvalued or undervalued?

As of May 30, 2025, Centenial Surgic is considered very attractive and undervalued with a PE ratio of -32.38, an EV to EBITDA of 10.18, and a Price to Book Value of 1.68, especially when compared to competitors like Max Healthcare and Apollo Hospitals, while also boasting a strong 1-year stock return of 40.95%.

As of 30 May 2025, the valuation grade for Centenial Surgic has moved from very expensive to very attractive, indicating a significant shift in its market perception. The company appears to be undervalued, especially when considering its current PE ratio of -32.38, an EV to EBITDA of 10.18, and a Price to Book Value of 1.68. These figures suggest that despite the negative earnings reflected in the PE ratio, the company's valuation metrics are more favorable compared to its peers.<BR><BR>In comparison to notable competitors, Max Healthcare has a PE ratio of 100.29 and an EV to EBITDA of 62.71, while Apollo Hospitals shows a PE of 69.03 and an EV to EBITDA of 34.71. This stark contrast highlights Centenial Surgic's attractive valuation relative to its peers in the healthcare services industry. Additionally, the company's strong stock performance, with a 1-year return of 40.95% compared to the Sensex's 7.62%, reinforces the narrative that it is currently undervalued in the market.

What is the technical trend for Centenial Surgic?

As of June 6, 2025, Centennial Surgic's technical trend is mildly bullish, supported by the weekly MACD and Bollinger Bands, although caution is advised due to mixed signals from the monthly indicators and short-term bearishness in daily moving averages.

As of 6 June 2025, the technical trend for Centenial Surgic has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive outlook, while the monthly MACD is mildly bearish, indicating some caution. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the upward momentum. The Dow Theory also shows a mildly bullish stance on both weekly and monthly charts. However, the daily moving averages are mildly bearish, suggesting short-term weakness. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some mixed signals from the monthly indicators.

Who are the top shareholders of the Centenial Surgic?

The top shareholders of Centenial Surgic are Vijay Kalidas Majrekar with 22.62%, and Kartik Shyam Kingar with 16.7%. Individual investors own a combined 50.29%, with no institutional holdings reported.

The top shareholders of Centenial Surgic include Vijay Kalidas Majrekar, who holds the highest promoter stake at 22.62%. The highest public shareholder is Kartik Shyam Kingar, with a holding of 16.7%. Additionally, individual investors collectively own 50.29% of the company. There are no institutional holdings from mutual funds or foreign institutional investors.

Has Centenial Surgic declared dividend?

No Dividend History Available